MedTrace Logo

Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration

NCT00710229 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2010-06-09

No results posted yet for this study

Summary

Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic processes in the eye. This forms the basis for new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the FDA and one drug is used off-label. All these drugs are administered intravitreally. The present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular AMD.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Ranibizumab

intravitreal injection

DRUG

Bevacizumab

intravitreal injection

Sponsors & Collaborators

  • Krankenanstalt Rudolfstiftung

    collaborator UNKNOWN

  • Medical University of Vienna

    collaborator OTHER

  • Medical University of Graz

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • Krankenhaus der Barmherzigen Brüder Linz

    collaborator OTHER

  • Universitätsaugenklinik Salzburg

    collaborator UNKNOWN

  • Hospital Hietzing

    collaborator OTHER

  • Hanuschkrankenhaus

    collaborator UNKNOWN

  • The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710229 on ClinicalTrials.gov